Implications of the Biden IRA on the value proposition of new drugs
Little attention is being focused on the impact the Inflation Reduction Act (IRA) may have on pharmaceutical R&D pipeline assets currently in Phase II or early Phase III of development. Precision's Kathy Lang and Ross Maclean outline challenges with assessing the true value of innovations that will have implications for IRA assessments, and propose suggestions around the importance of early planning to mitigate several elements of risk that manufacturers will face.